REGENERON PHARMACEUTICALS, INC. - FORM 10-Q - EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - November 4, 2015

Attached files

file filename
EX-10.2 - IO LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN THE REGISTRANT AND SANOFI - REGENERON PHARMACEUTICALS, INC.regn-ex_102x09302015x10q.htm
EX-10.1 - IO DISCOVERY AND DEVELOPMENT AGREEMENT BY AND BETWEEN THE REGISTRANT AND SANOFI - REGENERON PHARMACEUTICALS, INC.regn-ex_101x09302015x10q.htm
EX-10.3 - AMENDED AND RESTATED DISCO. AGREEMENT BY AND BETWEEN THE REGISTRANT AND SANOFI - REGENERON PHARMACEUTICALS, INC.regn-ex_103x09302015x10q.htm
EX-10.5 - SECOND AMENDMENT TO WARRANTS BETWEEN MORGAN STANLEY AND THE REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_105x09302015x10q.htm
EX-10.7 - COLLABORATION AGREEMENT BY AND BETWEEN REGENERON IRELAND AND MITSUBISHI TANABE - REGENERON PHARMACEUTICALS, INC.regn-ex_107x09302015x10q.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex_312x09302015x10q.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex_311x09302015x10q.htm
EX-10.6 - SEVENTEENTH AMENDMENT TO LEASE BY AND BETWEEN BMR-LANDMARK AND THE REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_106x09302015x10q.htm
EX-10.4 - AMENDED AND RESTATED COLLAB. AGREEMENT BY AND BETWEEN THE REGISTRANT AND SANOFI - REGENERON PHARMACEUTICALS, INC.regn-ex_104x09302015x10q.htm
10-Q - FORM 10-Q - REGENERON PHARMACEUTICALS, INC.regn-093015x10q.htm


Exhibit 32
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Regeneron Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Leonard S. Schleifer, M.D., Ph.D., as Principal Executive Officer of the Company, and Robert E. Landry, as Principal Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Leonard S. Schleifer
Leonard S. Schleifer, M.D., Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
November 4, 2015
 
/s/ Robert E. Landry
Robert E. Landry
Senior Vice President, Finance and Chief Financial Officer
(Principal Financial Officer)
November 4, 2015




REGENERON PHARMACEUTICALS, INC. Reports